ReviewWorld journal of diabetes2016
Early detection of diabetic kidney disease: Present limitations and future perspectives.
Review in World journal of diabetes, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 79 citations in OpenAlex.
- Fractional Excretion of Total Protein and Long-Term Kidney Outcomes in Patients With Biopsy-Proven Diabetic Nephropathy: The N-BDN Study.Diabetes, obesity & metabolism · 2026Observational
- Economic Impact of PromarkerD In Vitro Diagnostic Testing on the Management of Chronic Kidney Disease in Type 2 Diabetes: A Budget Impact Analysis.PharmacoEconomics - open · 2026Article
- Article
- Article
- Diabetes Duration Is Associated with Declining Kidney Function: eGFR and CKD Burden Across Duration.Journal of clinical medicine · 2026Article
- Article
- Novel biomarkers for CKD risk stratification: a literature review.Jornal brasileiro de nefrologia · 2026Review
- Evaluation of serum moesin and podocalyxin levels in patients with diabetes mellitus.Open medicine (Warsaw, Poland) · 2026Article
- Urinary CFHR2 as a Biomarker for Early Diagnosis and Disease Progression Prediction in Diabetic Kidney Disease.Current molecular medicine · 2026Article
- Role of novel biomarkers urinary NGAL and MCP-1 in predicting progression of diabetic kidney disease in type 2 DM.Renal failure · 2025Observational
- Association between serum spexin levels and diabetic nephropathy in patients with type 2 diabetes: a cross-sectional study.International urology and nephrology · 2025Article
- Sodium-Glucose Cotransporter-2 Inhibitor Improves Renal Injury by Regulating the Redox Profile, Inflammatory Parameters, and Pyroptosis in an Experimental Model of Diabetic Kidney Disease.ACS pharmacology & translational science · 2025Article
- PromarkerD Versus Standard of Care Biochemical Measures for Assessing Future Renal Function Decline in Type 2 Diabetes.Diagnostics (Basel, Switzerland) · 2025Article
- Serum adropin levels as a potential biomarker for predicting diabetic kidney disease progression.Frontiers in endocrinology · 2025Article
- Towards clinical translation of urinary vitronectin for non-invasive detection and monitoring of renal fibrosis in kidney transplant patients.Journal of translational medicine · 2024Article
- Article
- Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a potential early biomarker for diabetic nephropathy: a meta-analysis.International journal of biochemistry and molecular biology · 2024Article
- Diagnostic challenges of diabetic kidney disease.Biochemia medica · 2023Review
- Metabolomic Investigation of Blood and Urinary Amino Acids and Derivatives in Patients with Type 2 Diabetes Mellitus and Early Diabetic Kidney Disease.Biomedicines · 2023Article
- Exosomes in Diabetic Kidney Disease.Kidney diseases (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) is one of the most common diabetic complications, as well as the leading cause of chronic kidney disease and end-stage renal disease around the world. To prevent the dreadful consequence, development of new assays for diagnostic of DKD has always been the priority in the research field of diabetic complications. At present, urinary albumin-to-creatinine ratio and estimated glomerular filtration rate (eGFR) are the standard methods for assessing glomerular damage and renal function changes in clinical practice. However, due to diverse tissue involvement in different individuals, the so-called "non-albuminuric renal impairment" is not uncommon, especially in patients with type 2 diabetes. On the other hand, the precision of creatinine-based GFR estimates is limited in hyperfiltration status. These facts make albuminuria and eGFR less reliable indicators for early-stage DKD. In recent years, considerable progress has been made in the understanding of the pathogenesis of DKD, along with the elucidation of its genetic profiles and phenotypic expression of different molecules. With the help of ever-evolving technologies, it has gradually become plausible to apply the thriving information in clinical practice. The strength and weakness of several novel biomarkers, genomic, proteomic and metabolomic signatures in assisting the early diagnosis of DKD will be discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.